Werewolf Therapeutics (NASDAQ:HOWL) Announces Earnings Results, Misses Estimates By $0.03 EPS

Werewolf Therapeutics (NASDAQ:HOWL) released its earnings results on Tuesday. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.03), Zacks reports. Werewolf Therapeutics had a negative net margin of 578.80% and a negative return on equity of 58.83%.

Werewolf Therapeutics Price Performance

Shares of NASDAQ HOWL traded down $0.01 during mid-day trading on Thursday, reaching $1.23. The company’s stock had a trading volume of 48,965 shares, compared to its average volume of 266,069. The stock has a fifty day moving average of $1.37 and a two-hundred day moving average of $1.82. The firm has a market capitalization of $54.59 million, a PE ratio of -0.81 and a beta of 0.37. Werewolf Therapeutics has a 52 week low of $1.03 and a 52 week high of $6.89. The company has a debt-to-equity ratio of 0.29, a current ratio of 10.10 and a quick ratio of 10.10.

Analysts Set New Price Targets

Several research analysts have recently commented on HOWL shares. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Werewolf Therapeutics in a research note on Wednesday. Wedbush restated an “outperform” rating and set a $8.00 target price on shares of Werewolf Therapeutics in a research note on Wednesday. Finally, JMP Securities dropped their price target on shares of Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating for the company in a research report on Tuesday, January 14th.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.